

A young girl with dark hair is shown in profile, blowing a dandelion seed. The background is a bright, green field under a clear blue sky. The dandelion seed is in the foreground, and many other seeds are visible in the air, creating a sense of movement and freshness.

# UNIGENE

A leader in the design, delivery, manufacture and development of peptide-based therapeutics

*February 2012*

## **Corporate Presentation**

Ticker: UGNE.OB

[www.unigene.com](http://www.unigene.com)

# Safe Harbor Statement

*Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This presentation contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based upon Unigene Laboratories, Inc.'s management's current expectations, estimates, beliefs, assumptions, and projections about Unigene's business and industry. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Unigene's cash flow, market acceptance risks, technical development risks and other risk factors detailed in Unigene's Securities and Exchange Commission filings.*

# Why Invest in Unigene?



- Most clinically advanced (Ph3/NDA) and well validated oral peptide delivery technology platform
- Positive Ph2 proof-of-concept results of oral PTH; actively seeking licensing partner
- Positive Ph3 results for potential first oral calcitonin to market; Unigene owns ~20% of licensee, Tarsa
- Eight feasibility studies under Biotechnologies SBU; anticipate licensing agreement within 6-9 months
- Proprietary lead compound expected to file IND for morbid obesity
- 50:50 Joint Venture with Nordic Bioscience targeting Type 2 diabetes

Key elements in place to address debt in 2012

# Therapeutic Peptides are Medically Important and Growing Rapidly

70 Peptide-based Therapeutics Approved

316 Active Clinical Trial Peptide Programs




Source: <http://www.medtrack.com>(January2012)

# High Growth/Return Strategy

## Unigene Therapeutics


*Pipeline of Novel Peptides Focused On Metabolic & Inflammatory Disease*




- Proprietary shots on goal
- High ROI potential from partnering

## Unigene Biotechnologies

*Portfolio of Proprietary Peptide Partnerships*



- Near-term cash from service fees
- Licensing milestones and royalties 

# Unigene Biotechnologies



# Peptide Development Partner of Choice

*Peptelligence™* platform validated with eight feasibility studies across a broad spectrum of high valuation therapeutic areas

- Cardiovascular, metabolic disease, endocrinology, growth disorders, gynecology, oncology, CNS and pain


Limited potential due to route of administration

Life cycle management

Development stage peptides with questionable commercial viability

Drug Delivery Partnerships 2011 Industry Achievement Award Winner


# Definitive License Agreement Anticipated within 6-9 Months



# Unigene Therapeutics



# Advanced Internal Pipeline Focused on Metabolic & Inflammatory Diseases



# 20% Ownership in Tarsa – Oral Calcitonin NDA Filing H2 2012

- Unigene's oral delivery platform validated by positive results of Ph3 osteoporosis trial
  - Achieved primary endpoint with statistical significance under SPA
- Oral sCT was superior to nasal sCT and placebo at primary endpoint absent clinically significant food effects
- Potential to be first oral sCT product to cannibalize and then expand upon a ~\$600MM injectable/nasal sCT market
- NDA filing scheduled H2 2012
- Ph2 osteopenia (osteoporosis prevention) study results expected Q3 2012

## **Unigene Owns 20%\* of Tarsa**


**Unigene eligible to receive sales-related milestone payments**

**Unigene eligible to receive royalties on worldwide sales**

# Successful Ph2 Oral PTH Study

- Primary endpoint achieved in Ph2 Study
  - Oral PTH (5mg) resulted in a statistically significant mean increase in BMD at lumbar spine of 2.2 percent ( $p < 0.001$ ) at week 24 as compared to baseline
- No serious drug related adverse events
  - no incidences of hypercalcemia
- Compelling proof-of-concept achieved and actively seeking advanced-stage development/commercialization partner
- Injectable PTH is only anabolic therapy approved for osteoporosis
  - ~\$1B market opportunity projected to grow to ~\$2B by 2018
- Consistent PK exposure with desired pulsatile profile for PTH anabolic activity validates precision of our oral delivery technology

# Ph2 Results: Mean PTH Cmax Values for Subjects Receiving Oral PTH



# Metabolic Disease Programs

- UGP281 lead molecule
  - Targeting morbidly obese population to optimize risk benefit relationship
  - Favorable pharmacological profile potentially addressing many of the shortfalls of recent obesity drug failures
  - Incorporates Unigene's oral formulation and high-yield manufacturing technology
  - Expected to file IND in 2012
- New proprietary analogs
  - Unigene peptide library screened for biological activity by Nordic Bioscience
  - Three high potential analogs selected for advanced evaluation, characterization and development

# 50:50 JV with Nordic– Selection of Lead Molecule for T2D Q2 2012

- Nordic Bioscience is an ideal joint development partner
  - Nordic’s world renowned preclinical screening, biomarker and clinical development capabilities combined with Unigene’s peptide design and development expertise
- Opportunity to access multiple blockbuster markets
  - Type 2 diabetes, osteoarthritis and osteoporosis
- Unigene selected by Nordic over other potential partners
  - Reinforced by Nordic Chairman’s \$6MM investment option
- Preclinical results for lead molecule expected before year end

Validates Unigene as peptide development partner of choice



*Applied Peptelligence*

# Unigene Corporate



# Management with Proven Track Record

<b>Ashleigh Palmer</b> President and CEO	25+ years general management experience; Ikaria/INO Therapeutics, Ohmeda, Critical Biologics Corp, Creative BioVentures™ Corp
<b>Greg Mayes, Esq.</b> Chief Business Officer	15 years of biopharma legal and commercial experience; Eli Lilly, ImClone Systems, AstraZeneca, Morgan Lewis LLP
<b>Nozer Mehta, Ph.D.</b> VP, Research and Development	33+ years R&D experience; 28 years with Unigene, Research Asst. Prof. University of Nebraska, Lincoln
<b>Paul Shields, Ph.D.</b> VP, Manufacturing Operations	21+ years manufacturing and operations experience with Unigene
<b>Roxanne Tavakkol</b> VP, Global Regulatory Affairs and Quality Assurance	20+ years regulatory experience; The Medicines Company, Novartis
<b>Jenene Thomas</b> VP, IR and Business Administration	14 years IR experience; Amicus, Aeterna Zentaris, Savient, Reliant, Pharmacia

**Currently recruiting CFO in preparation for next phase of growth**

# Next Generation Board of Directors

<b>Richard Levy</b> Chairman	<b>Managing Principal and Founder, Victory Park Capital</b>
<b>Ashleigh Palmer</b> Director	<b>President and CEO</b>
<b>Zvi Eiref</b> Director	<b>Financial Expertise</b> <i>Church &amp; Dwight Co., Inc. CFO for 20 years</i>
<b>Joel A. Tune</b> Director	<b>Business Development, Product Development and Commercial Expertise</b> <i>Baxter 30 years</i>
<b>Theron (Ted) Odlaug Ph.D.</b> Director	<b>Manufacturing, Regulatory, Quality Assurance and Operational Expertise</b> <i>CyDex, Fujisawa Healthcare, Astellas Pharma</i>
<b>Thomas J. Sabatino, Jr.</b> Director	<b>Legal and Healthcare Expertise</b> <i>Walgreens Co., United, Schering Plough, Baxter, American Medical</i>

# Financial Snapshot

## Current cash projections expected to fund operations into H2 2012

Market Cap as of 2/9/12	\$50MM
Cash Position as of 9/30/11	\$5.2MM <sup>(1)</sup>
Debt as of 9/30/11 <i>(VPC holds \$33MM in convertible debt at \$0.70 due 3/2013)</i>	\$48MM <sup>(2)</sup>
2011 Net Burn	~\$1.5MM per quarter
Fully Diluted Shares Outstanding <i>(including \$33MM conversion)</i>	172MM









### Strong support from Victory Park Capital

- Chairman of the Board
- Can retire \$33MM of Unigene's \$48MM debt if fully converted
- Confidence in new strategic plan and management team
- Purchased shares on open market




*(1) Excludes Q4 related revenue announcements; (2) Principal only*

Key elements in place to address debt in 2012

# Management's 2011 Scorecard

	Launched a targeted growth strategy with two distinct value creation engines
	Extended the cash runway by 18 months without additional financing/debt
	Transformed BD/partnering to a core competence
	Validated oral delivery technology platform with positive Phase 3 oral calcitonin results
	Advanced an inactive oral PTH program to a positive Ph2 proof-of-concept asset
	Divested several distracting non-core assets
	Advanced UGP281 obesity program from early preclinical to a pre-IND asset
	Formed a 50:50 JV with Nordic Bioscience to develop calcitonin analogs for blockbuster indications/markets

# 2012 Near-Term Catalysts

	Q1 2012	Q2 2012	Q3 2012	Q4 2012
<b>Therapeutics Business Unit</b>				
<b>Oral PTH Program</b>				
		<ul style="list-style-type: none"> <li>• Full data presentation of Ph2 results in peer review journal /presentation at scientific congress</li> </ul>		
<b>Oral Calcitonin</b>			<ul style="list-style-type: none"> <li>• Ph2 Osteopenia study results</li> </ul>	<ul style="list-style-type: none"> <li>• Ostora™ NDA filing H2 2012</li> </ul>
<b>UGP281 (morbid obesity)</b>			<ul style="list-style-type: none"> <li>• IND Filing</li> </ul>	<ul style="list-style-type: none"> <li>• Commence Ph1 study</li> </ul>
<b>50:50 Nordic JDV</b>		<ul style="list-style-type: none"> <li>• Selection of lead molecule for T2D indication</li> </ul>	<ul style="list-style-type: none"> <li>• T2D preclinical results</li> </ul>	
<b>Biotechnologies Business Unit</b>				
<b>Peptelligence™</b>				
				
<b>Cara Therapeutics</b>	<ul style="list-style-type: none"> <li>• Ph1 results</li> </ul>			

# Unigene Represents a Compelling Investment Opportunity

- Most clinically advanced (Ph3/NDA) and well validated oral peptide delivery technology platform
- Positive Ph2 proof-of-concept results of oral PTH; actively seeking licensing partner
- Positive Ph3 results for potential first oral calcitonin to market; Unigene owns ~20% of licensee, Tarsa
- Eight feasibility studies under Biotechnologies SBU; anticipate licensing agreement within 6-9 months
- Proprietary lead compound expected to file IND for morbid obesity
- 50:50 Joint Venture with Nordic Bioscience targeting Type 2 diabetes

Key elements in place to address debt in 2012

A young girl with dark hair is shown in profile, blowing a dandelion seed. The background is a bright, green field under a clear blue sky. The dandelion seed is in the foreground, and many other seeds are visible in the air, suggesting a breeze.

# UNIGENE

A leader in the design, delivery, manufacture and development of peptide-based therapeutics

*February 2012*

## **Corporate Presentation**

Ticker: UGNE.OB

[www.unigene.com](http://www.unigene.com)